Despite recent exponential growth in research on familial hypercholesterolaemia, there remains a general lack of public and health professional awareness about the disorder.

Although myeloproliferative neoplasms are rare illnesses, the general practitioner is well placed to identify suspicious features and initiate investigations and referral.

Beliefs about the usefulness of initiatives to reduce opioid prescribing in clinical practice and autonomy in prescribing may be important considerations in driving compliance.